Cargando…
Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2
Poly (ADP-ribose) polymerase inhibitor (PARPi)-based therapies initially reduce tumor burden but eventually lead to acquired resistance in cancer patients with BRCA1 or BRCA2 mutation. To understand the potential PARPi resistance mechanisms, we performed whole-genome CRISPR screens to discover genet...
Autores principales: | Tang, Mengfan, Pei, Guangsheng, Su, Dan, Wang, Chao, Feng, Xu, Srivastava, Mrinal, Chen, Zhen, Zhao, Zhongming, Chen, Junjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287926/ https://www.ncbi.nlm.nih.gov/pubmed/34197614 http://dx.doi.org/10.1093/nar/gkab540 |
Ejemplares similares
-
SLX4IP acts with SLX4 and XPF–ERCC1 to promote interstrand crosslink repair
por: Zhang, Huimin, et al.
Publicado: (2019) -
Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in DNA replication dynamics controlled by ATR
por: Dhoonmoon, Ashna, et al.
Publicado: (2020) -
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
por: Giovannini, Sara, et al.
Publicado: (2019) -
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
por: Huang, Fei, et al.
Publicado: (2016) -
Genetic vulnerabilities upon inhibition of DNA damage response
por: Wang, Chao, et al.
Publicado: (2021)